Law360, New York (May 09, 2012, 7:38 PM ET) -- A New Jersey court on Friday dismissed a Wockhardt Ltd. subsidiary from litigation claiming versions of the heartburn medication Reglan caused users to develop a neurological disorder, rejecting a theory advanced by plaintiffs nationwide attempting to dodge the U.S. Supreme Court's Mensing decision.
The plaintiffs in the instant suit contended that Morton Grove Pharmaceuticals Inc. became the de facto brand-name manufacturer of the syrup form of Reglan when the U.S. Food and Drug Administration named the company's product as the reference point for establishing bioequivalency —...
Suits Against Reglan Generics Can't Skirt Mensing: NJ Court
To view the full article, take a free trial now.
